F8 and hemophilia A: In 2018, the first non-factor replacement therapy, emicizumab, was approved for use in Europe for long-term PPX in people of all ages who have congenital hemophilia A with FVIII inhibitors or severe congenital hemophilia A (FVIII<1%) without FVIII inhibitors [4, 9, 10].